

If it is important to enable televisits for DCT trials, embedding the feature directly into the eCOA app brings multiple benefits for patients and sites.

Why use the Kayentis televisit feature for your DCT trials?

If it is important to enable televisits for DCT trials, embedding the feature directly into the eCOA app brings multiple benefits for patients and sites



▶ BRINGING SIGNIFICANT COMFORT AND SUPPORTING PATIENT COMPLIANCE

The Televisit feature provides assurance that the study will continue even if the patient does not come to the study site, and:

- Maintains direct contact between sites and patients from anywhere
- Is easily accessible from the eCOA app on the same device
- Is particularly relevant when :
 - The patient cannot come to site for a given study visit
 - The site cannot perform the patient visit for a certain period of time (eg, pandemic)
 - The patient and site staff need to talk outside of the visit schedule
- The physical presence of the patient is not required on site

▶ REDUCING THE STUDY SITE BURDEN

- Increased **flexibility** for study staff
- **Reduced burden** of multiple login credentials
- Simplified site-patient connection with only **one click** needed to contact the patient



▶ ENSURING A HIGH LEVEL OF CONTROL

- The **timestamp** of the televisit is stored in the audit trail
- **As only authorized sites (and their patients) can perform televisits**, sponsors will also be able to keep control of their use and adapt their strategy according to the specifics of the study sites

Kayentis Televisit: Plan for the unplanned

A simple televisit solution, activable by the site at any time


- ✓ **Flexible solution for the sponsor:** Activable at any time of the study
- ✓ **Easy to set up:** no impact on the set-up timelines
- ✓ **Easy-to-use for patients:** a single app for both data collection and televisits with single sign-on
- ✓ **Easy-to-use for sites:** televisits can be initiated in one click, at any time, even outside of the visit schedule
- ✓ **Audit trail of televisits:** date, duration, patient & site identification
- ✓ **Confidentiality:** content of the televisit remains confidential with no recording

Contact us for more information at sales@kayentis.com



Download the infographic
Contact us for more information

Learn more:



The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

5 February 2024

In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy

[Read More »](#)



The relevance of ePROs in early phase clinical trials

31 January 2024

Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the

[Read More »](#)



3 considerations to take into account when setting up an eCOA clinical trial

29 January 2024

In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains

[Read More »](#)



Kayentis operational excellence

23 January 2024

Why do customers recommend Kayentis for operational excellence? More than 95% of Kayentis customers recommend

[Read More »](#)



Innovation and Partnerships: The Biotech Perspective

16 January 2024

In the ever-evolving landscape of biotechnology, groundbreaking advancements continue to shape the future of healthcare.

[Read More »](#)



Exploring The Specific Challenges Of Pediatric Clinical Trials – Insights From Site Experts

22 November 2023

In this first episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)